IMPE Abstracts

Osteogenesis imperfecta (OI) is a genetic disease characterized by alterations in type I collagen, which determine a broad spectrum of clinical alterations. Although there is no specific treatment, drugs of the bisphosphonate class are used with the aim of improving bone quality with a reduction in fracture events and a gain in quality of life. In Brazil, current protocols use pamidronate, a second-generation bisphosphonate. The use of zoledronic acid, a third-generation bisph...